/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present 14 abstracts from across its sleep...

Related Keywords

Ireland , Seattle , Washington , United States , Dublin , Japan , Rio De Janeiro , Estado Do Rio , Brazil , American , Japanese , Logan Schneider , Andrean Flynn , Kristin Bhavnani , Rob Iannone , Onset Rapid Eye Movement Periods , Jazz Pharmaceuticals , Head Of Global Corporate Communications , Idiopathic Hypersomnia Total Health Model , Nasdaq , Unmet Public Health Problem , American Academy Of Sleep Medicine , National Academies Press , Stanford Va Alzheimer Center , Jazz Pharmaceuticals Inc , Drug Enforcement Agency , United States Drug Enforcement Agency , International Classification Of Sleep Disorders , Health Outcomes , Indian Journal Of Medical Research , Stanford Sleep Center , Office Of Orphan Product Development , American Psychiatric Association , World Sleep Society , Drug Administration , National Institute Of Neurological Disorders , National Health Service , Jazz Pharmaceutical , World Sleep , Consultant Neurologist , Sleep Medicine , Dosing Strategies , Idiopathic Hypersomnia , Healthcare Resource Utilization , Disrupted Nighttime , Narcolepsy Detection Paradigm , From Real World , Patients Transitioning From , Pediatric Narcolepsy , Clinically Important Difference , Analog Scale , Sleep Inertia , Two Neurological , Based Analysis , Sodium Oxybate , With Narcolepsy , Post Hoc , Orphan Drug Exclusivity , Orphan Product Development , Risk Evaluation , Mitigation Strategy , Safety Information , Prescribing Information , Boxed Warning , Global Corporate , Neurological Disorders , Accessed October , Sleep Deprivation , Narcolepsy Disease , Sleep Med , International Classification , Third Edition , Statistical Manual , Fifth Edition , Expert Opin Investig , Palo Alto , States Drug Enforcement , Jazz Pharmaceuticals Plc ,